Table 1 Demographic and clinical characteristics of patients with mucormycosis

Age (years)

39.98 ± 18.52

38.46 ± 20.71

40.51 ± 17.97

Male sex

26(52.0)

10(76.9)

16(43.2)

Underlying diseases

Acute myeloid leukaemia

23(46.0)

5(38.5)

18(48.6)

Acute lymphoblastic leukaemia

8(16.0)

3(23.1)

5(13.5)

Myelodysplastic syndrome

8(16.0)

0(0.0)

8(21.6)

Recurrent aplastic anemia

8(16.0)

4(30.8)

4(10.8)

Chronic myeloid leukemia

2(4.0)

1(7.7)

1(2.7)

Primary myelofibrosis

1(2.0)

0(0.0)

1(2.7)

Underlying diseases status^a

25(50.0)

5(38.5)

20(54.1)

Comorbidity^b

Hypertension

8(16.0)

3(23.1)

5(13.5)

Cerebral infarction

3(6.0)

0(0.0)

3(8.1)

Hepatitis B

2(4.0)

1(7.7)

1(2.7)

Others^c

3(6.0)

2(15.4)

1(2.7)

Laboratory data

White blood cell (× 10⁹/L)

1.86 ± 2.35

2.57 ± 2.70

1.61 ± 2.19

Neutrophil (× 10⁹/L)

1.20 ± 1.94

2.15 ± 2.70

0.84 ± 1.47

Hemoglobin(g/L)

63.94 ± 17.78

62.69 ± 15.39

64.35 ± 18.73

Blood platelet (× 10¹²/L)

23.58 ± 17.96

32.62 ± 25.53

20.41 ± 13.48

Neutrophil count <0.5 × 10⁹/L

30(60.0)

7(53.8)

23(63.2)

Duration of neutropenia (day)

17.87 ± 12.914

14.36 ± 13.171

18.94 ± 12.828

Haematopoietic stem cell

transplantation

15(30.0)

3(23.1)

12(32.4)

Prior voriconazole

36(72.0)

5(38.5)

31(83.8)

Number of chemotherapy

3.38 ± 3.428

2.38 ± 2.755

3.73 ± 3.603